Wedbush raised the firm’s price target on SpringWorks Therapeutics (SWTX) to $81 from $77 and keeps an Outperform rating on the shares ...

Merck KGaA (MKGAY) confirms “advanced discussions” with Springworks Therapeutics (SWTX) regarding a potential acquisition. “Merck also confirms that no legally binding agreement has been ...

Merck KGaA said it’s in advanced talks to purchase SpringWorks Therapeutics Inc., sending shares of the US cancer and rare diseases drugmaker soaring. One of SpringWorks’ drugs, Ogsiveo ...

Merck KGaA, the German healthcare and technology group, is in advanced talks to acquire U.S. cancer and rare diseases ...

Germany’s Merck KGaA is in advanced talks to acquire SpringWorks, Reuters first reported Monday, citing people close to the matter. After the report, Merck KGaA later confirmed (PDF) the ...

NEW YORK/FRANKFURT (Reuters) - Merck KGaA, the German healthcare and technology group, said on Monday it is in advanced talks to acquire U.S. cancer and rare diseases drugmaker SpringWorks ...

Update 2:15pm: Adds Merck KGaA confirmation. SpringWorks Therapeutics (NASDAQ:SWTX) soared ~40% after a report that Merck KGaA (OTCPK:MKGAF) is in advanced discussions to acquire the cancer and ...

NEW YORK/FRANKFURT (Reuters) - Merck (NSE:PROR) KGaA, the German healthcare and technology group, is in advanced talks to acquire U.S. cancer and rare diseases drugmaker Springworks Therapeutics ...

Germany's Merck KGaA is in advanced talks to buy U.S. cancer and rare diseases biotech company Springworks Therapeutics, Reuters says, citing unnamed sources. -- The deal could be finalized in the ...

Investing.com -- Shares of Springworks Therapeutics (NASDAQ:SWTX) surged over 37% on Monday following reports that Germany’s Merck (NSE:PROR) KGaA is in advanced talks to acquire the U.S ...

Idrees Abbas / SOPA Images / LightRocket / Getty Images Shares of SpringWorks Therapeutics soared on Monday following a report that German medical firm Merck KGaA could acquire the company.